Absci (ABSI) Enterprise Value (2021 - 2026)
Absci (ABSI) posted Enterprise Value of -$125.7 million for Q1 2026, up 12.88% sequentially from -$144.3 million in Q4 2025, and up 6.18% YoY from -$118.4 million in Q1 2025.
Analysis
Absci (ABSI) Enterprise Value (2021 - 2026) Analysis & Trends
Absci has reported Enterprise Value for 7 years, with the latest figure at -$125.7 million in Q1 2026.
- Quarterly Enterprise Value rose 6.18% year-over-year to -$125.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$125.7 million (up 6.18% YoY) and the FY2025 annual result came in at -$144.3 million, down 28.35% from the prior year.
- Enterprise Value grew to -$125.7 million in Q1 2026 per ABSI's latest filing, from -$144.3 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$50.0 million in Q2 2022 and troughed at -$226.0 million in Q1 2022.
- A 5-year average of -$136.6 million and a median of -$134.0 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value slumped 180.74% in 2022, then jumped 40.61% in 2023.
- Over 5 years, Enterprise Value stood at -$164.4 million in 2022, then surged by 40.61% to -$97.7 million in 2023, then decreased by 15.12% to -$112.4 million in 2024, then declined by 28.35% to -$144.3 million in 2025, then rose by 12.88% to -$125.7 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$125.7 million, -$144.3 million, and -$152.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.79 Bn |
| Mar 31, 2026 | 342.01 Mn |
| Dec 31, 2025 | 389.75 Mn |
| Sep 30, 2025 | 304.65 Mn |
| Jun 30, 2025 | 266.82 Mn |
| Mar 31, 2025 | 186.19 Mn |
| Dec 31, 2024 | 189.82 Mn |
| Sep 30, 2024 | 309.14 Mn |
| Jun 30, 2024 | 204.16 Mn |
| Mar 31, 2024 | 480.29 Mn |
| Dec 31, 2023 | 293.31 Mn |
| Sep 30, 2023 | 9.20 Mn |
| Jun 30, 2023 | 16.15 Mn |
| Mar 31, 2023 | 17.59 Mn |
| Dec 31, 2022 | 29.63 Mn |
| Sep 30, 2022 | 109.42 Mn |
| Jun 30, 2022 | 102.01 Mn |
| Mar 31, 2022 | 556.60 Mn |
| Dec 31, 2021 | 154.85 Mn |
| Sep 30, 2021 | 573.12 Mn |